MX2022016065A - Formas solidas de 3 -((1r, 3r)-1-(2,6-difluoro-4 -((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-t etrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden una porcion de fenilo o piridinilo sustituido, incluyendo metodos de uso. - Google Patents

Formas solidas de 3 -((1r, 3r)-1-(2,6-difluoro-4 -((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-t etrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden una porcion de fenilo o piridinilo sustituido, incluyendo metodos de uso.

Info

Publication number
MX2022016065A
MX2022016065A MX2022016065A MX2022016065A MX2022016065A MX 2022016065 A MX2022016065 A MX 2022016065A MX 2022016065 A MX2022016065 A MX 2022016065A MX 2022016065 A MX2022016065 A MX 2022016065A MX 2022016065 A MX2022016065 A MX 2022016065A
Authority
MX
Mexico
Prior art keywords
difluoro
solid forms
difluoropropan
fluoropropyl
azetidin
Prior art date
Application number
MX2022016065A
Other languages
English (en)
Inventor
Hans Iding
Francis Gosselin
Alec Fettes
Haiming Zhang
Ngiap- Kie Lim
Paroma Chakravarty
Karthik Nagapudi
Cheol Keun Chung
Jie Xu
Kyle Clagg
Michael Dalziel
Andrew Mcclory(Finado)
Sarah Robinson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022016065A publication Critical patent/MX2022016065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proveen formas sólidas, sales tales como el Compuesto B, y formulaciones de 3-((1R,3R)-1-(2,6-difluoro-4-((1-( 3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahi dro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, procesos y síntesis de estos y métodos para su uso en el tratamiento del cáncer.
MX2022016065A 2018-06-21 2020-10-29 Formas solidas de 3 -((1r, 3r)-1-(2,6-difluoro-4 -((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-t etrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden una porcion de fenilo o piridinilo sustituido, incluyendo metodos de uso. MX2022016065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687930P 2018-06-21 2018-06-21
US201862719896P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
MX2022016065A true MX2022016065A (es) 2023-02-02

Family

ID=67441580

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020011531A MX2020011531A (es) 2018-06-21 2019-06-17 Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3 il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3 ,4-b]indol-2-il)-2,2 difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso.
MX2023006785A MX2023006785A (es) 2018-06-21 2020-10-29 Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso.
MX2022016065A MX2022016065A (es) 2018-06-21 2020-10-29 Formas solidas de 3 -((1r, 3r)-1-(2,6-difluoro-4 -((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-t etrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden una porcion de fenilo o piridinilo sustituido, incluyendo metodos de uso.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020011531A MX2020011531A (es) 2018-06-21 2019-06-17 Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3 il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3 ,4-b]indol-2-il)-2,2 difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso.
MX2023006785A MX2023006785A (es) 2018-06-21 2020-10-29 Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso.

Country Status (29)

Country Link
US (2) US10954234B2 (es)
EP (2) EP3810283B1 (es)
JP (4) JP6916969B1 (es)
KR (2) KR20230117761A (es)
CN (2) CN112437685A (es)
AU (3) AU2019290545B2 (es)
BR (1) BR112020024073A2 (es)
CA (1) CA3098203A1 (es)
CL (1) CL2020003022A1 (es)
CO (1) CO2020014604A2 (es)
CR (2) CR20230409A (es)
DK (1) DK3810283T3 (es)
ES (1) ES2951829T3 (es)
FI (1) FI3810283T3 (es)
HR (1) HRP20230859T1 (es)
HU (1) HUE064542T2 (es)
IL (1) IL278063A (es)
LT (1) LT3810283T (es)
MX (3) MX2020011531A (es)
PE (1) PE20211207A1 (es)
PH (1) PH12020500676A1 (es)
PL (1) PL3810283T3 (es)
PT (1) PT3810283T (es)
RS (1) RS64429B1 (es)
SG (1) SG11202012171SA (es)
SI (1) SI3810283T1 (es)
TW (1) TW202016098A (es)
UA (1) UA128114C2 (es)
WO (1) WO2019245974A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951829T3 (es) 2018-06-21 2023-10-25 Hoffmann La Roche Formas sólidas de la sal de tartrato de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)acetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, proceso para su preparación y procedimientos de su uso en el tratamiento de cánceres
EP4106760A4 (en) * 2020-05-07 2024-03-27 Recurium Ip Holdings Llc COMBINATIONS
US11918561B2 (en) 2020-05-12 2024-03-05 Genentech, Inc. Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
US20230348459A1 (en) * 2020-05-15 2023-11-02 Simcere Pharmaceutical Co., Ltd. Pyrrolidine compound and use thereof
JP7419575B2 (ja) 2020-06-28 2024-01-22 メッドシャイン ディスカバリー インコーポレイテッド 縮合環インダゾール系化合物
PE20230853A1 (es) 2020-06-30 2023-05-29 Genentech Inc Procesos para elaborar compuestos serd triciclicos que tienen un resto sustituido de fenilo o piridinilo
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators
TW202237099A (zh) * 2021-02-16 2022-10-01 美商建南德克公司 使用包含ｇｄｃ－９５４５及帕他色替之組合療法治療乳癌
IL304911A (en) * 2021-02-16 2023-10-01 Genentech Inc Breast cancer treatment using combination therapies including GDC-9545 and abemciclib or ribociclib
CN117813288A (zh) 2021-07-15 2024-04-02 西藏海思科制药有限公司 芳氨基衍生物***受体调节剂及其用途
CN114656444A (zh) * 2022-03-04 2022-06-24 河北松辰医药科技有限公司 一种2,2-二氟-1,3-丙基磺酸内酯的合成方法
WO2023209062A1 (en) 2022-04-28 2023-11-02 F. Hoffmann-La Roche Ag Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种***受体降解剂化合物及其制备方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7414572L (es) 1973-12-06 1975-06-09 Endo Lab
SE455604B (sv) 1982-06-29 1988-07-25 Stiftelsen Ind Organisk Elektr Sett att framstella fenetylaminer medelst elektrokemisk reduktion
DE3639329C1 (de) 1986-11-18 1988-02-25 Heesemann Karl Masch Bandschleifmaschine
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
RU14873U1 (ru) 2000-06-26 2000-09-10 Закрытое акционерное общество "Патентные услуги" Комбинированная машина непрерывного литья заготовок
ATE298570T1 (de) 2000-12-08 2005-07-15 Smithkline Beecham Corp Antibakterielle verbindungen
JP4220779B2 (ja) 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2004089470A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2005034857A2 (en) 2003-09-05 2005-04-21 Sequella, Inc. Methods and compositions comprising diamines as new anti-tubercular therapeutics
RU2387652C2 (ru) 2004-03-11 2010-04-27 Актелион Фармасьютиклз Лтд Производные тетрагидропиридоиндола
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
SG184755A1 (en) 2004-03-15 2012-10-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
EP1786425A1 (en) 2004-08-02 2007-05-23 SmithKline Beecham Corporation Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
EP1968934A4 (en) 2006-01-02 2014-02-26 Hetero Drugs Ltd METHOD FOR OBTAINING PURE OSELTAMIVIR
AU2008239598A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
MX2010011868A (es) 2008-04-29 2010-11-26 Novartis Ag Derivados de espiro-indol para el tratamiento de enfermedades parasitarias.
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
WO2010015815A2 (en) 2008-08-05 2010-02-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
DE102009006545B4 (de) 2009-01-29 2017-08-17 Epcos Ag Überspannungsableiter und Anordnung von mehreren Überspannungsableitern zu einem Array
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
AU2010232642A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-piperidine compounds
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
MX2020005345A (es) 2009-05-27 2022-07-18 Ptc Therapeutics Inc Un método para inhibir o reducir una infección viral por coronavirus.
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2011150162A1 (en) 2010-05-27 2011-12-01 Ptc Therapeutics, Inc. Methods for treating viral conditions
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CN104508126B (zh) 2012-03-23 2017-06-30 科德克希思公司 用于合成色胺和色胺类似物的衍生物的生物催化剂和方法
WO2013139987A1 (en) 2012-03-23 2013-09-26 Novartis Ag Chemical process for preparing spiroindolones and intermediates thereof
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
US9643982B2 (en) 2013-05-17 2017-05-09 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
SI3004090T1 (en) 2013-05-28 2018-01-31 Astrazeneca Ab Chemical compounds
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
SG11201509508YA (en) 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP3062791B1 (en) 2013-10-28 2020-01-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
MX2016007282A (es) 2013-12-06 2016-09-07 Hoffmann La Roche Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
RU2016137150A (ru) 2014-03-13 2018-04-18 Ф. Хоффманн-Ля Рош Аг Способы и композиции для модулирования мутантов эстрогеновых рецепторов
MA39741A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
KR102505901B1 (ko) 2014-06-27 2023-03-08 노그라 파마 리미티드 아릴 수용체 조정제, 및 그의 제조 및 사용 방법
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 ***受体调节剂及其用途
JP2017538727A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
EA032311B1 (ru) * 2014-12-18 2019-05-31 Ф. Хоффманн-Ля Рош Аг Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение
JP6776348B2 (ja) 2015-10-01 2020-10-28 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
EP3954372A1 (en) * 2016-02-01 2022-02-16 Takeda Pharmaceutical Company Limited Cocrystal
WO2017136688A1 (en) 2016-02-05 2017-08-10 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
EP3472159A1 (en) * 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
ES2951829T3 (es) 2018-06-21 2023-10-25 Hoffmann La Roche Formas sólidas de la sal de tartrato de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)acetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, proceso para su preparación y procedimientos de su uso en el tratamiento de cánceres

Also Published As

Publication number Publication date
MX2023006785A (es) 2023-06-20
SI3810283T1 (sl) 2023-10-30
CL2020003022A1 (es) 2021-06-04
CR20200621A (es) 2021-02-03
IL278063A (en) 2020-11-30
JP6916969B1 (ja) 2021-08-11
US10954234B2 (en) 2021-03-23
MX2020011531A (es) 2021-03-25
LT3810283T (lt) 2023-08-25
EP4295845A3 (en) 2024-02-28
KR20230117761A (ko) 2023-08-09
RS64429B1 (sr) 2023-09-29
FI3810283T3 (fi) 2023-08-11
EP3810283B1 (en) 2023-06-14
CO2020014604A2 (es) 2020-12-10
EP3810283A1 (en) 2021-04-28
PH12020500676A1 (en) 2021-06-14
JP2024054111A (ja) 2024-04-16
CR20230409A (es) 2023-09-25
JP2021191750A (ja) 2021-12-16
HUE064542T2 (hu) 2024-03-28
WO2019245974A1 (en) 2019-12-26
CN117946107A (zh) 2024-04-30
AU2022202967B2 (en) 2024-02-22
CA3098203A1 (en) 2019-12-26
AU2022202967A1 (en) 2022-05-26
AU2019290545A1 (en) 2020-11-19
BR112020024073A2 (pt) 2021-02-17
JP2021191751A (ja) 2021-12-16
ES2951829T3 (es) 2023-10-25
CN112437685A (zh) 2021-03-02
PL3810283T3 (pl) 2023-10-16
US11780834B2 (en) 2023-10-10
HRP20230859T1 (hr) 2023-11-10
KR20210022701A (ko) 2021-03-03
AU2023229513A1 (en) 2023-10-05
PT3810283T (pt) 2023-08-18
KR102564647B1 (ko) 2023-08-11
UA128114C2 (uk) 2024-04-10
WO2019245974A8 (en) 2020-11-05
US20220041587A1 (en) 2022-02-10
PE20211207A1 (es) 2021-07-05
SG11202012171SA (en) 2021-01-28
JP2021522312A (ja) 2021-08-30
AU2019290545B2 (en) 2022-04-14
EP4295845A2 (en) 2023-12-27
DK3810283T3 (en) 2023-08-21
TW202016098A (zh) 2020-05-01
US20200002331A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2023006785A (es) Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso.
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
MX2020001302A (es) Procesos para preparar compuestos de pirrolidina.
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EP4233910A3 (en) Methods of treatment of cholestatic diseases
MX2010005556A (es) Procedimiento para la fabricacion de un derivado de indolinona.
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MY195271A (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
TW200833660A (en) Synthesis of pyrrolidine compounds
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
IN2012DN03844A (es)
MXPA05007339A (es) Derivados de alfa-aminoamida utiles como agentes antimigranosos.
MX2019000442A (es) Derivados de etinilo.
UY34170A (es) Formas cristalinas de 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida
AR114974A1 (es) Procesos para preparar compuestos tricíclicos fusionados que comprenden un resto piridinilo o fenilo sustituido, incluidos métodos para su uso
SI3655395T1 (sl) Postopek za pripravo N-((1R,2S,SR)-5-(TERT-butilamino)-2-((S)-3-(7- TERT-butilpirazolo(1,5-A)(1,3,5)triazin-4-ilamino)-2-oksopirolidin-1-il) cikloheksil) acetamida
TN2009000069A1 (en) Polymorph of (r) -3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azoni a-bicylco-[2.2.2]octane bromide
UA85198C2 (ru) Производные морфолина как ингибиторы повторного поглощения норэпинефрина
WO2018226178A3 (en) (E) -1- (4-CINNAMOYL-PHENYL) -1H-PYRROLE-2,5-DIONE DERIVATIVES WITH ANTI-CANCER EFFECT